Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From TechCrunch
By Marina Temkin
July 11, 2024
People in tech often say that data is the new oil. That phrase, coined by British mathematician Clive Humby, of course implies that data is valuable.
Data about a person’s health can also provide meaningful insights and improve outcomes, but only 3% of patient data is currently used by physicians, according to the World Economic Forum. Although doctors know they can glean useful information from patient data, they don’t have the time to review every detail in the medical record.
Regard, a digital health startup founded in 2017, wants to help physicians save time and increase the accuracy of diagnosis by analyzing patients’ health data using AI.
Regard announced on Thursday that it raised a $61 million Series B round led by Oak HC/FT, with participation from Cedars-Sinai Health Ventures and existing investors TenOneTen, Calibrate Ventures and Techstars. The company is now valued at $350 million, according to a person familiar with the matter.
The company’s software mines thousands of data points in a medical chart and presents data in a way that allows doctors to detect health conditions more easily.
“Doctors use our product because we help them make sure that nothing important is missed in the data,” Eli Ben-Joseph, Regard’s co-founder and CEO, told TechCrunch. “Every single doctor we work with has a story about: ‘I used your product and I found something that changed the way I treat this patient.”
Ben Joseph said that Regard has helped one general physician catch atrial fibrillation (irregular heartbeat) that the cardiologist did not notice. “She now feels it’s irresponsible not to use our product,” he said.
But doctors are not the only ones who find Regard valuable. Hospital financial administrators are also big fans, according to Ben-Joseph. Regard’s ability to identify new conditions creates new billing opportunities for medical systems.
The company has grown its revenue by 4.5 times in 2023 and is on a path to do a “similar amount of growth this year,” Ben-Joseph said. The company expects to reach profitability within the next two years.
Such fast growth has investors excited.
“We absolutely fell in love with [Regard] because it has a direct impact on physician productivity, burnout, proper coding and clinical outcomes,” said Nancy Brown, general partner at Oak HC/FT.
Brown, who has over 30 years of experience as an operator and investor in healthcare technology, has always dreamt that a computer would provide insights from patient information. “That dream has been foiled [over the years] by the lack of tech,” she said. That’s why when she met Ben-Joseph at a healthcare conference earlier this year, she instantly recognized that Regard is the technology she has been dreaming about.
Since launching its product in 2021, Regard has signed up a number of large healthcare systems, including Banner Health, one of Arizona’s largest health providers, Virginia-based Sentara Healthcare, New York’s Montefiore Medical Center and Cedars-Sinai Medical Center in Los Angeles. Some details of its latest funding round were previously reported by Business Insider.
The company’s competitors include Engage One, a product developed by multinational conglomerate 3M, and startup Pieces, according to Ben-Joseph.
Brown has no doubts that Regard is the leader in space. “They are a beautiful scaling company with great margins, and they are delivering a solid ROI for their clients,” she said.
Lately’s new gamified app helps people arrive on time
A new app called Lately launched on the App Store a few weeks ago, targeting people with ADHD to help them arrive on time and rewarding them for doing so. The service is designed to help users manage their travel plans by notifying them when it’s time to leave for a trip, sending reminders 30 minutes, 10 minutes, and 5 minutes before departure. It also features Live Activities on iPhone and Apple Watch that display a countdown to leave. To encourage timely departures, Lately employs a point rew
Apr 26, 2025
The OpenAI mafia: 15 of the most notable startups founded by alumni
Move over, PayPal mafia: There’s a new tech mafia in Silicon Valley. As the startup behind ChatGPT, OpenAI is arguably the biggest AI player in town. Its meteoric rise to a $300 billion valuation has spurred many employees to leave the AI giant to create startups of their own. The hype around OpenAI is so high that some of these startups, like Ilya Sutskever’s Safe Superintelligence and Mira Murati’s Thinking Machines Lab, have been able to raise billions of dollars without even launching a pro
Apr 26, 2025
Deel files countersuit against Rippling as rivalry escalates
In the latest development of an increasingly public dispute between HR and payroll services rivals, Deel has filed a countersuit against Rippling. To recap: Rippling publicly announced on March 17 that it was suing Deel over alleged corporate espionage, with accusations ranging from violation of the RICO racketeering act (typically used to prosecute organized crime) to misappropriation of trade secrets and unfair competition. Deel is now slamming that lawsuit as part of a “campaign to try to i
Apr 25, 2025